Contraceptive Failure Rates of Etonogestrel Subdermal Implants in Overweight and Obese Women

被引:75
|
作者
Xu, Hanna [1 ]
Wade, Jennifer A. [1 ]
Peipert, Jeffrey F. [1 ]
Zhao, Qiuhong [1 ]
Madden, Tessa [1 ]
Secura, Gina M. [1 ]
机构
[1] Washington Univ, Sch Med, Dept Obstet & Gynecol, Div Clin Res, St Louis, MO 63110 USA
来源
OBSTETRICS AND GYNECOLOGY | 2012年 / 120卷 / 01期
关键词
BODY-MASS INDEX; UNINTENDED PREGNANCY; UNITED-STATES; WEIGHT; PREVALENCE; ADULTS;
D O I
10.1097/AOG.0b013e318259565a
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
OBJECTIVE: To estimate the contraceptive failure rates of the etonogestrel subdermal contraceptive implant in overweight and obese women and compare failure rates with women of normal weight and women using intrauterine devices (IUDs). METHODS: The Contraceptive CHOICE Project is a large prospective cohort study designed to promote the use of long-acting reversible contraceptive methods to reduce unintended pregnancies in the St Louis region. Participants are provided reversible contraception of their choice at no cost. We collected baseline height and weight of each participant. During each survey, participants were asked about missed menses and possible pregnancies. Any participant who suspected a pregnancy was asked to come in for urine pregnancy testing. Analysis includes the first 8,445 participants enrolled in CHOICE of which 1,168 chose the implant and 4,200 chose the IUD. Student's t test, chi(2) test, and Kaplan-Meier survival curves were used to perform statistical analyses to estimate failure rates in overweight and obese women using the implant and IUDs. RESULTS: Of the women choosing the implant, 28% were overweight and 35% were obese. Of the women who chose an IUD, 27% were overweight and 35% were obese. The 3-year cumulative failure rates for implant and IUD users were less than one per 100 women-years and did not vary by body mass index. CONCLUSION: We found no decrease in the effectiveness of the implant in overweight or obese women. The implant may be offered as a first-line contraceptive method to any woman seeking a reversible and reliable birth control method. (Obstet Gynecol 2012; 120: 21-6) DOI: 10.1097/AOG.0b013e318259565a LEVEL OF EVIDENCE: II
引用
收藏
页码:21 / 26
页数:6
相关论文
共 50 条
  • [31] Avoiding controversy in international provision of subdermal contraceptive implants
    Hubacher, David
    Dorflinger, Laneta
    CONTRACEPTION, 2012, 85 (05) : 432 - 433
  • [32] ADOLESCENT GIRLS ATTITUDES TOWARD CONTRACEPTIVE SUBDERMAL IMPLANTS
    DABROW, SM
    MERRICK, CL
    CONLON, M
    JOURNAL OF ADOLESCENT HEALTH, 1995, 16 (05) : 360 - 366
  • [33] Pilot study of a novel, alternative subdermal scapular insertion site for the etonogestrel contraceptive implant
    Clure, Cara
    Sheeder, Jeanelle
    Lazorwitz, Aaron
    CONTRACEPTION, 2024, 135
  • [34] EFFECT OF SUBDERMAL LEVONORGESTREL CONTRACEPTIVE IMPLANTS, NORPLANT, ON LIVER FUNCTIONS
    SHAABAN, MM
    ELWAN, SI
    ELSHARKAWY, MM
    FARGHALY, AS
    CONTRACEPTION, 1984, 30 (05) : 407 - 412
  • [35] PRELIMINARY REPORT ON CONTRACEPTIVE USE OF SUBDERMAL IMPLANTS CONTAINING NORETHINDRONE
    TEJUJA, S
    MALHOTRA, U
    BHINDER, G
    CONTRACEPTION, 1974, 10 (04) : 361 - 374
  • [36] Reproductive outcomes of oocyte donors using subdermal etonogestrel implants and levonorgestrel intrauterine devices
    Blazquez, A.
    Miguel-Escalada, I.
    Forcada, C.
    Correa-Manas, N.
    Popovic, M.
    Mataro, D.
    Rodriguez, A.
    HUMAN REPRODUCTION, 2024, 39 : I478 - +
  • [37] MECHANISM OF CONTRACEPTIVE ACTION OF NORETHISTERONE ENANTHATE ADMINISTERED BY SUBDERMAL IMPLANTS
    SRIVASTAVA, UK
    JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1978, 9 (09): : 866 - 866
  • [38] OVULATION DETECTION FOLLOWING REMOVAL OF LEVONORGESTREL SUBDERMAL CONTRACEPTIVE IMPLANTS
    ISMAIL, AAA
    ANWAR, MY
    YOUSSEF, SM
    TOPPOZADA, M
    CONTRACEPTION, 1987, 35 (03) : 207 - 214
  • [39] NORPLANT CONTRACEPTIVE SUBDERMAL IMPLANTS - ONE YEAR EXPERIENCE IN SINGAPORE
    SINGH, K
    VIEGAS, OAC
    RATNAM, SS
    CONTRACEPTION, 1988, 37 (05) : 457 - 469
  • [40] Ovarian cysts in users of Implanon® and Jadelle® subdermal contraceptive implants
    Hidalgo, MM
    Lisondo, C
    Juliato, CT
    Espejo-Arce, X
    Monteiro, I
    Bahamondes, L
    CONTRACEPTION, 2006, 73 (05) : 532 - 536